Biocept hopes to raise up to $24.25M from IPO

09/25/2013 | GenomeWeb Daily News (free registration)

Biocept said in a regulatory filing that it looks to obtain as much as $24.25 million in an initial public offering. The California-based company specializes in cancer assays based on circulating tumor cells as well as circulating tumor DNA diagnostics, which employ blood specimens.

View Full Article in:

GenomeWeb Daily News (free registration)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Vice-President of Technology and Regulatory Affairs
AdvaMed
Washington DC, DC
Sr Product Manager Global Marketing (US/DA/00/0085/SL) - 14000009V3
Abbott
Chicago, IL
Director of Medicare Products
Bluegrass Family Health
Lexington, KY
Director of Medicare Products
Bluegrass Family Health
Lexington, KY
Vice President, Information Technology
HealthPartners
MN